Abstract

Being vastly different from the human counterpart, we suggest that the last enzyme of the Mycobacterium tuberculosis Coenzyme A biosynthetic pathway, dephosphocoenzyme A kinase (CoaE) could be a good anti-tubercular target. Here we describe detailed investigations into the regulatory features of the enzyme, affected via two mechanisms. Enzymatic activity is regulated by CTP which strongly binds the enzyme at a site overlapping that of the leading substrate, dephosphocoenzyme A (DCoA), thereby obscuring the binding site and limiting catalysis. The organism has evolved a second layer of regulation by employing a dynamic equilibrium between the trimeric and monomeric forms of CoaE as a means of regulating the effective concentration of active enzyme. We show that the monomer is the active form of the enzyme and the interplay between the regulator, CTP and the substrate, DCoA, affects enzymatic activity. Detailed kinetic data have been corroborated by size exclusion chromatography, dynamic light scattering, glutaraldehyde crosslinking, limited proteolysis and fluorescence investigations on the enzyme all of which corroborate the effects of the ligands on the enzyme oligomeric status and activity. Cysteine mutagenesis and the effects of reducing agents on mycobacterial CoaE oligomerization further validate that the latter is not cysteine-mediated or reduction-sensitive. These studies thus shed light on the novel regulatory features employed to regulate metabolite flow through the last step of a critical biosynthetic pathway by keeping the latter catalytically dormant till the need arises, the transition to the active form affected by a delicate crosstalk between an essential cellular metabolite (CTP) and the precursor to the pathway end-product (DCoA).

Highlights

  • More than a century, a vaccine and several chemotherapeutic agents later, Mycobacterium tuberculosis continues its deadly march claiming several thousand lives each year [1,2]

  • With mycobacteria investing a major part of their coding capacity towards fatty acid synthesis, there being a whopping 250 distinct enzymes involved in fatty acid metabolism and 9% of all cellular activities employing Coenzyme A (CoA) as a cofactor (BRENDA database), targeting the tubercular CoA biosynthesis holds potential in globally impairing the pathogen, as CoA is involved in a variety of critical cellular processes, the chief being the synthesis of the cell wall mycolic acids [3]

  • The choice of the CoA biosynthetic pathway for investigation is lent credence by the fact that this pathway is essential in a majority of the prokaryotic pathogens, any deletions leading to growth stasis or lethality

Read more

Summary

Introduction

A vaccine and several chemotherapeutic agents later, Mycobacterium tuberculosis continues its deadly march claiming several thousand lives each year [1,2]. With mycobacteria investing a major part of their coding capacity towards fatty acid synthesis, there being a whopping 250 distinct enzymes involved in fatty acid metabolism and 9% of all cellular activities employing Coenzyme A (CoA) as a cofactor (BRENDA database), targeting the tubercular CoA biosynthesis holds potential in globally impairing the pathogen, as CoA is involved in a variety of critical cellular processes, the chief being the synthesis of the cell wall mycolic acids [3]. Evolutionary evidence points out that this universal biosynthetic pathway branched out early during the evolutionary history of life on earth and the present day eukaryotic and prokaryotic CoA-synthetic machinery differs vastly, with major differences in the basic architecture of the pathway and the regulation of individual steps [7]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.